First Tracks Biotherapeutics (TRAXV) director granted RSUs and options

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Dennis M. Fenton reported new equity awards tied to the spin-off from AnaptysBio and his board service. He now directly holds 4,965 shares of common stock received in the pro rata distribution from AnaptysBio.

On April 20, 2026, he acquired 4,000 and 6,030 Restricted Stock Units, each RSU representing one share of common stock upon settlement for no consideration. He also received multiple stock options to buy First Tracks common stock at exercise prices ranging from $3.97 to $31.82 per share with expirations between 2028 and 2036. Some options are fully vested, while others vest monthly starting February 6, 2026, and certain RSUs vest 100% on the company’s 2026 and 2027 annual meeting dates.

Insider Trade Summary

13 transactions reported

Mixed 13 txns

Insider FENTON DENNIS M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	6,000	$0.00	--
Grant/Award	Stock Option (right to buy)	5,507	$0.00	--
Grant/Award	Stock Option (right to buy)	6,000	$0.00	--
Grant/Award	Stock Option (right to buy)	11,000	$0.00	--
Grant/Award	Stock Option (right to buy)	11,000	$0.00	--
Grant/Award	Stock Option (right to buy)	9,200	$0.00	--
Grant/Award	Stock Option (right to buy)	10,600	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	16,510	$0.00	--
Grant/Award	Stock Option (right to buy)	5,500	$0.00	--
Grant/Award	Restricted Stock Unit	6,030	$0.00	--
Grant/Award	Restricted Stock Unit	4,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 6,000 shares (Direct, null); Restricted Stock Unit — 6,030 shares (Direct, null); Common Stock — 4,965 shares (Direct, null)

Footnotes (1)

1. Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio"). Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Direct common shares held: 4,965 shares RSU grant 1: 4,000 RSUs RSU grant 2: 6,030 RSUs +4 more

7 metrics

Direct common shares held 4,965 shares Common Stock held directly after transactions

RSU grant 1 4,000 RSUs Each RSU equals 1 common share upon settlement

RSU grant 2 6,030 RSUs Each RSU equals 1 common share upon settlement

Option grant at $11.75 5,500 options at $11.75/share Stock Option, expires January 6, 2036

Option grant at $3.97 16,510 options at $3.97/share Stock Option, expires January 6, 2035

Option grant at $5.67 16,510 options at $5.67/share Stock Option, expires January 2, 2034

Option grant at $6.22 10,600 options at $6.22/share Stock Option, expires January 5, 2033

Key Terms

Restricted Stock Unit, Stock Option (right to buy), Separation and Distribution Agreement, pro rata distribution, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (right to buy) financial

"Stock Option (right to buy) with conversion or exercise prices between 3.9700 and 31.8200"

Separation and Distribution Agreement regulatory

"pursuant to the Separation and Distribution Agreement dated as of April 20, 2026"

pro rata distribution financial

"Effective as of a pro rata distribution by AnaptysBio to holders of its shares"

A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.

vests as to 1/12 of the total shares monthly financial

"The stock option vests as to 1/12 of the total shares monthly"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FENTON DENNIS M

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								4,965(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$31.82	04/20/2026		A(2)		6,000		(3)	03/04/2028	Common Stock	6,000	$0	6,000	D
Stock Option (right to buy)	$31.82	04/20/2026		A(2)		5,507		(3)	03/04/2028	Common Stock	5,507	$0	5,507	D
Stock Option (right to buy)	$18.43	04/20/2026		A(2)		6,000		(3)	02/07/2029	Common Stock	6,000	$0	6,000	D
Stock Option (right to buy)	$4.43	04/20/2026		A(2)		11,000		(3)	02/11/2030	Common Stock	11,000	$0	11,000	D
Stock Option (right to buy)	$7.95	04/20/2026		A(2)		11,000		(3)	02/09/2031	Common Stock	11,000	$0	11,000	D
Stock Option (right to buy)	$8.14	04/20/2026		A(2)		9,200		(3)	02/09/2032	Common Stock	9,200	$0	9,200	D
Stock Option (right to buy)	$6.22	04/20/2026		A(2)		10,600		(3)	01/05/2033	Common Stock	10,600	$0	10,600	D
Stock Option (right to buy)	$5.67	04/20/2026		A(2)		16,510		(3)	01/02/2034	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$3.97	04/20/2026		A(2)		16,510		(3)	01/06/2035	Common Stock	16,510	$0	16,510	D
Stock Option (right to buy)	$11.75	04/20/2026		A(2)		5,500		(4)	01/06/2036	Common Stock	5,500	$0	5,500	D
Restricted Stock Unit	(5)	04/20/2026		A(6)		6,030		(7)	(7)	Common Stock	6,030	$0	6,030	D
Restricted Stock Unit	(5)	04/20/2026		A(6)		4,000		(8)	(8)	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").

2. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

3. The stock option is fully vested and exercisable.

4. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

5. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

6. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

7. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

8. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Ajim Tamboli, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Dennis M. Fenton receive from First Tracks Biotherapeutics (TRAXV)?

Dennis M. Fenton received 4,000 and 6,030 Restricted Stock Units and several stock option grants to acquire First Tracks common stock. These awards stem from the AnaptysBio spin-off adjustments and his ongoing service as a director of First Tracks Biotherapeutics.

Did Dennis M. Fenton buy or sell First Tracks (TRAXV) shares in the market?

There were no open-market purchases or sales reported. The filing shows equity grants and spin-off related adjustments, including RSUs and stock options, rather than discretionary buying or selling of First Tracks common stock by Dennis M. Fenton.

How many First Tracks (TRAXV) common shares does Dennis M. Fenton now hold directly?

Dennis M. Fenton holds 4,965 shares of First Tracks common stock directly. These shares were received through the pro rata distribution in connection with the spin-off from AnaptysBio, as described in the Separation and Distribution Agreement dated April 20, 2026.

What are the key terms of Dennis M. Fenton’s stock options in First Tracks (TRAXV)?

Fenton holds several stock options to buy First Tracks common stock, including 5,500 options at $11.75 per share and 16,510 options at $3.97 per share. Expiration dates range from 2028 through 2036, with some options fully vested and others vesting monthly.

How and when do Dennis M. Fenton’s RSUs in First Tracks (TRAXV) vest?

Each RSU gives Fenton the right to receive one share of First Tracks common stock for no cash consideration. One RSU grant vests 100% on the company’s 2026 annual meeting date, and another vests 100% on the 2027 annual meeting date, subject to continued service.

How is the AnaptysBio spin-off related to these First Tracks (TRAXV) awards?

Under the April 20, 2026 Separation and Distribution Agreement, AnaptysBio’s existing options and RSUs were adjusted into awards covering both AnaptysBio and First Tracks shares. As a result, Fenton acquired First Tracks stock options and RSUs in amounts determined by that agreement.